Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Receivables - Accured (2022 - 2025)

Zentalis Pharmaceuticals has reported Receivables - Accured over the past 4 years, most recently at $1.9 million for Q4 2025.

  • Quarterly results put Receivables - Accured at $1.9 million for Q4 2025, down 34.49% from a year ago — trailing twelve months through Dec 2025 was $1.9 million (down 34.49% YoY), and the annual figure for FY2025 was $1.9 million, down 34.49%.
  • Receivables - Accured for Q4 2025 was $1.9 million at Zentalis Pharmaceuticals, down from $2.2 million in the prior quarter.
  • Over the last five years, Receivables - Accured for ZNTL hit a ceiling of $3.3 million in Q4 2023 and a floor of $266000.0 in Q1 2022.
  • Median Receivables - Accured over the past 4 years was $2.0 million (2023), compared with a mean of $1.9 million.
  • Biggest five-year swings in Receivables - Accured: skyrocketed 719.48% in 2024 and later tumbled 34.83% in 2025.
  • Zentalis Pharmaceuticals' Receivables - Accured stood at $508000.0 in 2022, then soared by 556.89% to $3.3 million in 2023, then decreased by 11.81% to $2.9 million in 2024, then plummeted by 34.49% to $1.9 million in 2025.
  • The last three reported values for Receivables - Accured were $1.9 million (Q4 2025), $2.2 million (Q3 2025), and $2.5 million (Q2 2025) per Business Quant data.